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Abstract
Objective: The aim is to characterize subgroups or phenotypes of rheumatoid arthritis (RA) patients using a systems biology
approach. The discovery of subtypes of rheumatoid arthritis patients is an essential research area for the improvement of
response to therapy and the development of personalized medicine strategies.
Methods: In this study, 39 RA patients are phenotyped using clinical chemistry measurements, urine and plasma
metabolomics analysis and symptom profiles. In addition, a Chinese medicine expert classified each RA patient as a Cold or
Heat type according to Chinese medicine theory. Multivariate data analysis techniques are employed to detect and validate
biochemical and symptom relationships with the classification.
Results: The questionnaire items ‘Red joints’, ‘Swollen joints’, ‘Warm joints’ suggest differences in the level of inflammation
between the groups although c-reactive protein (CRP) and rheumatoid factor (RHF) levels were equal. Multivariate analysis
of the urine metabolomics data revealed that the levels of 11 acylcarnitines were lower in the Cold RA than in the Heat RA
patients, suggesting differences in muscle breakdown. Additionally, higher dehydroepiandrosterone sulfate (DHEAS) levels
in Heat patients compared to Cold patients were found suggesting that the Cold RA group has a more suppressed
hypothalamic-pituitary-adrenal (HPA) axis function.
Conclusion: Significant and relevant biochemical differences are found between Cold and Heat RA patients. Differences in
immune function, HPA axis involvement and muscle breakdown point towards opportunities to tailor disease management
strategies to each of the subgroups RA patient.
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Introduction
Discovering subtypes of rheumatoid arthritis (RA) patients is
considered a key research area for the improvement of response to
therapy [1,2]. RA is a heterogeneous disease which is illustrated by
the very good response of some patients to a biological therapy,
but a complete lack of response in a large number of other patients
[3]. Another striking observation is that in a large group of RA
patients low disease activity or remission can be achieved using a
single conventional disease-modifying anti-rheumatic drug
(DMARD), which contrasts with the current viewpoint to offer
aggressive therapy in an early stage of the disease to all patients
[4]. Personalized medicine aims to provide the information that
allows targeting the right treatment option to the right patient [5].
The first step in this approach is to find relevant subtypes of
patients for which a different treatment strategy would clearly be
beneficial.
Several subtypes of RA patients have been identified based on
particular clinical and molecular features [6,7]. Markers such as
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disease duration and age have been identified that predict
response to treatment [8,9]. Although some molecular markers
have been found to predict functional and structural outcomes,
these markers rarely find their way into clinical practice. One
reason is the difficulty to translate markers found in trial
populations to routinely measurable and cost-effective predictors
for individuals [10]. This indicates that there is a need to develop
new robust and reliable clinically applicable tools to identify
subtypes of patients.
Discovery of novel relevant subtypes of RA patients could be
improved by using prior knowledge. In this study a Chinese
perspective on subtypes of RA patients is used to focus the analysis
of the data. According to this perspective RA patients can be
divided in two groups (Cold RA and Heat RA) which are treated
very differently in Chinese medical practice [11,12].
Cold and Heat are general concepts used in Chinese medicine
to distinguish between two types of reactions of the body to some
disturbance [13]. A Cold reaction is characterized by pallor,
intolerance of cold, absence of thirst, loose stools, clear profuse
urine, a pale tongue and a slow pulse. A Heat reaction is
characterized by flushed face, fever, thirst, irritability, restlessness,
constipation, deep-colored urine, reddened tongue and a rapid
pulse [14]. These two types of reactions are expressed in any type
of disease to a certain extend. However, Cold and Heat are
especially important for rheumatoid arthritis because this disease is
perceived in classical Chinese medicine as the result of an invasion
of three out of the four existing external pathogens: Wind, Cold,
Heat and Damp [13].
Some work has been done to elucidate biological mechanisms
related to Cold and Heat types of RA patients. In 2009 we
measured 64 differently expressed genes in CD4 positive T-cells of
RA patients. This set of genes was enriched for the immune system
functions and especially for apoptosis regulation. In Heat RA
patients apoptosis related genes were upregulated while in Cold
patients apoptosis resitance genes were upregulated [11]. Addi-
tionally, a number of plasma metabolite concentrations was
significantly different between Cold and Heat RA. Later, genes
related to calcium signaling, cell adhesion, PPAR signaling and
fatty acid metabolism were found in CD4 positive T-cells of Heat
RA patients [15]. Toll-like receptor signaling related genes were
found in the T-cells of Cold RA patients. In a similar study, Cold
RA was related to Alanine, aspartate and tyosine metabolism and
Heat RA to the MAPK pathway, Wnt signaling and insulin
signaling, also found by measuring gene expression in CD4
positive T-cells [16]. A GC-MS analysis of Cold and Heat RA
plasma revealed elevated plasma levels of glycochenodeoxycho-
late, proline, saturated and mono-unsaturated phosphatidylcholine
(PC) but decreased levels of urea, free fatty acid (FFA) and
polyunsaturated PC in Heat RA compared to Cold RA [17].
Recently it was shown that Cold RA patients respond much
better to a combination therapy with diclofenac, methotrexate
and sulfasalazine than Heat RA patients [18]. However, in
clinical studies and clinical practice the features of Cold and
Heat might be valued differently by each Chinese medicine
practitioner. To improve acceptance of this classification in
Western clinical practice it is important to standardize the
classification. Further characterization of the physiological,
constitutional and biological differences between the Cold and
Heat subtypes of RA patients is valuable for increasing our
understanding of the disease mechanism.
In this study a systems biology strategy is employed to study
the differences between Cold and Heat types of RA patients,
classified by a Chinese medicine expert. Data were collected on
symptoms, clinical blood parameters and urine metabolites.
Multivariate statistics were employed to discover the most
discriminating features for the two groups. In particular, a
categorical principal component analysis [19,20] was used for the
questionnaire and clinical chemistry data and partial least
squares discriminant analysis is used for the metabolomics data
[21]. The questionnaire was used to determine symptom patterns
related to Cold and Heat RA that could be used in clinical
practice to determine these subtypes in an objective manner. The
metabolomics and clinical results were related to biological
processes and related to current understanding of the heteroge-
neity of rheumatoid arthritis.
Subjects and Methods
Subjects
Female subjects were recruited in the Zhejiang Xinhua Hospital
in 2010. The institutional review board of the hospital gave written
approval and judged that the study was conducted according to
the ethical guidelines. A doctor explained the details of the study to
the subjects and ensured written informed consent of each subject.
All eligible subjects were diagnosed by a rheumatologist as
rheumatoid arthritis patients according to the ACR criteria [22].
Inclusion criteria were a female gender due to the much higher
prevalence of RA in women and age .18 years. Each patient was
classified by the same Chinese medicine expert as either a Heat
subtype or a Cold subtype. When the subtype was unclear the
patient was not included in the study. General information such as
age, disease duration, medication, etc. was collected using a
standard form. Student’s t-Test (two-tailed) was used to evaluate
the differences between the two groups. Furthermore, a symptom
questionnaire was completed by all the patients. Blood and urine
samples were taken from each patient after fasting overnight for
routine clinical measurements and metabolomics analysis.
Symptom Questionnaire
A short version of a recently developed systems diagnosis
questionnaire was used in this study [23]. The 106 item
questionnaire was shortened to 57 items by two Chinese medicine
experts to target it more directly to Cold and Heat related
symptoms. The final version of the questionnaire contained items
related to five categories of symptoms: breathing, digestion,
climate, quality of the symptoms and pain. The questionnaire
was translated into Chinese. An English language version of the
questionnaire is added as supplementary information (Text S1).
The consistency of the data was checked and the data were
recoded [23].
Clinical Measurements
Routine clinical chemistry measurements were conducted on
fasting blood samples by the Zhejiang Xinhua Hospital. These
measurements consisted of the complete blood count and the
following serum measurements: uric acid (URIC), creatinine
(CREA), blood urea nitrogen (BUN), triglycerides (TG), choles-
terol (CHOL), total protein (TP), albumin (ALB), globulines (BIB),
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), creatine kinase (CK), creatine kinase-MB (CKMB), lactate
dehydrogenase (LDH), immunoglobulin A (IGA), Immunoglobu-
lin G (IGG), immunoglobulin M (IGM), complement 3 (C3),
complement 4 (C4), antistreptolysin O (ASO), rheumatoid factor
(RHF), c-reactive protein (CRP), anti-cyclic citrullinated protein
antibodies (CCP). The results of each clinical parameter were
uniformly binned into 19 categories to increase the robustness
[19].
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Metabolomics Measurements
Urine samples were prepared for Ultra Fast LC/MS-IT-TOF
(Shimadzu, Japan) analysis [24]. The technical variation of the
analysis over time was monitored by a pooled quality control (QC)
sample strategy [25]. The analysis was performed on a Ultra Fast
LC/MS-IT-TOF with gradient elution using 0.1% formic acid in
water as mobile phase A and 0.1% formic acid in acetonitrile as
mobile phase B. For the LC a T3 column (ACQUITY UPLC HSS
T3 1.8um, 2.16100 mm, Waters) was used. Ion mode was
switched between positive and negative mode between each scan
[24].
Sample preparation for the plasma metabolomics analysis was
conducted as follows: 200 mL plasma was mixed with 800 mL
acetonitrile, then the mixture was centrifuged at 14000 rpm
(Biofuge Stratos, Thermo Scientific, USA) for 10 min at 4uC. The
supernatant was freeze-dried and redissolved with 200 mL of 20%
acetonitrile.
Chromatographic separation was performed on a BEH C8
column (10 cm62.1 mm, 1.7 mm, Waters, USA) using a Thermo
Fisher Accela LC system. The gradient duration was 31 min at a
flow rate of 300 mL/min with mobile phase (A) 0.1% formic acid
solution and (B) acetonitrile. The injection volume was 6 mL. The
samples were analyzed randomly and the same QC strategy was
used as in the urine analysis.
An LC-MS method was used to measure the plasma metabo-
lites. The LTQ-Orbitrap XL (Thermo-Fisher Scientific) settings
were as follows: capillary temperature 325uC, source voltage
4.5 kV, capillary voltage 49 V for ESI+analysis; capillary temper-
ature 325uC, source voltage 23.5 kV, capillary voltage 240 V for
ESI- analysis. The mass range was set at 100–1000 m/z. The
resolution of the Orbitrap was set at 30000.
The urine metabolomics measurements resulted in a list of
features after preprocessing the data using Profiling Solution
(Shimadzu, Japan) [24]. The plasma metabolomics data were
processed by SIEVE software (V1.2, Thermo-Fisher Scientific) for
peak picking and peak alignment. The parameter of MZ width
was set at 0.01 Da and RT width was set at 0.6 min. Gradient
peaks were removed. Features not present in at least 80% of the
samples in one class were removed. Zeros were replaced by the
smallest measured value divided by 2, the urine data were mean
centered and the plasma data was autoscaled. Principal compo-
nent analysis was then used to screen the data for outliers (objects
with scores deviating from the scores of the bulk of the samples)
[26], to determine the stability of the analysisover time (by
comparing the scores of the QC samples) and monitor possible
batch effects (by checking possible time trends in the scores of the
objects).
Statistical Analysis
Questionnaire and clinical chemistry data. The focus of
the data analysis is to identify questionnaire items and clinical
parameters that distinguish between the subgroups of RA patients
classified by the CM expert. A forced classification approach [27]
using Nonlinear Principal Component Analysis (NLPCA) was
chosen. NLPCA is a Principal Component Analysis method that is
suitable for variables with mixed measurement level and variables
that may have nonlinear relationships to each other [19]. The
possibility to capture nonlinear relationships is important because
the human body is a nonlinear system expressing complex
behavior [28]. Such complex behavior has been observed in the
immune system that plays a key role in rheumatoid arthritis. For
instance cytokine dose response curves show an initial threshold
and stable attractors have been found in cytokine systems [29].
More important is the ability of NLPCA to deal with the
questionnaire data that are measured on an ordinal scale or as
binary data. The questionnaire data analysis approach using
NLPCA is described in detail in a previous paper [23].
NLPCA uses an ‘optimal scaling’ approach to find quantifica-
tions for categorical variables and optimal transformations for
interval variables, which means that the percentage of variance of
the transformed variables accounted for by the principal
components is maximal [30]. The questionnaire items and clinical
parameters were all included in a single NLPCA analysis allowing
the interpretation of relationships between questionnaire items and
clinical parameters.
The use of a the classification variable with a very large weight,
here 1000 will cause the objects to cluster together into subclouds
in the object space. The weight was chosen such that the objects of
both classes were separated completely. As the classification
variable is a binary variable, one principal component is sufficient
to describe the class differences. In this study we used CATPCA in
SPSS version 17.0 [31].
An important consideration in NLPCA is the analysis level
chosen for the variables [20]. For the questionnaire variables the
analysis level was kept the same as the measurement level (39
ordinal and 3 nominal). Subsequently the presence of nonlinear
relationships between the clinical chemistry variables and the
classification variable was examined by comparing numerical,
spline ordinal and spline nominal transformations of the clinical
chemistry variables (i.e., from most restricted to least restricted
transformations). A substantial increase in the total variance
accounted for (total VAF) due to an analysis level with more
degrees of freedom then verifies that a less restrictive model is
more appropriate.
After choosing the appropriate analysis level, variables with a
proportion variance accounted for (VAF) .0.20 were selected for
further analysis to increase the stability of the model and to focus
on the most important variables. Leave two out cross validation
was used to estimate the classification error of the model. In this
approach two objects are reserved as a validation set while a
NLPCA model is built using the other 37 objects. The class of the
two left out objects is then predicted using the NLPCA model.
This procedure is repeated until each of the objects is left out once
and the class of each object is predicted. An overall classification
error is subsequently calculated and a final model is built using all
the available objects. Permutation testing was used to check
whether this final model is different from a model based on a
random classification.
Metabolomics data. A partial least squares discriminant
analysis (PLS-DA) model was built for both the urine and plasma
data set to find the most discriminating features between the Cold
RA and Heat RA groups, a standard, well accepted technique
used in the metabolomics field to discover characteristic differ-
ences between groups [32]. A separate model for the urine and
plasma data was built to examine the performance of a metabolite
profile measured in one compartment in a single analysis. Such a
profile would be much easier to develop into a diagnostic tool that
can be applied in a clinical setting than a combination of two
metabolomics profiles.
A tenfold double cross-validation scheme was followed by
permutation testing (250 times) [33]. The inner loop of the cross-
validation scheme is used to estimate the optimal number of
principal components. In this inner loop two objects are left out to
validate the number of principal components. The outer loop is
used to estimate the error rate of the model. Again, in the outer
loop two objects are left out to independently estimate the error
rate. Variables were selected using a jack-knifing procedure in
which variables with a standard error in the regression vector
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above a threshold were removed from the dataset. This threshold
is decreased stepwise until the error rate of the model starts to
increase. The model with the lowest error rate is then chosen as
the optimal model and a final model is then built for the
corresponding set of variables and including all the objects.
Subsequently, the significance of the resulting model is determined
by permutation testing. The same double cross-validation proce-
dure is used to build a model of the same data set but with a
permuted classification. After 250 times permuting the classifica-
tion, the classification error of the 250 models resulting models is
compared with the classification error of the model based on the
correct classification. The error rate of the correct classification
model should be lower than 95% of the distribution of error rates
resulting from the permuted classifications.
Identification of the most discriminating features indicated by
the PLS-DA model was then attempted for both the urine and
plasma model [34]. Evidence for the identity of features was
accumulated by integrating information on the following: accurate
mass of the ions and some fragments, retention time, HMDB
database and in house human urine compound lists. The
identification of some compounds was then verified by authentic
standards. Finally, a biological interpretation was sought for the
most discriminating features.
Results
Subjects
In total 50 patients were enrolled in the study. Eleven of these
patients did not fulfill the inclusion criteria and were removed
from the analysis. Seven of those eleven patients were male and
therefore excluded, of two persons there was no RA diagnosis
available, one patient was in the hospital for other reasons and
therefore excluded and finally one person was excluded from this
analysis because the symptom questionnaire was not completed.
Finally, 20 RA patients of the Cold subtype and 19 of the Heat
subtype were retained in the study.
Table 1 shows the patient characteristics per group expressed as
the means of the age, disease duration, height and weight. None of
these characteristics were significantly different (p-value ,0.05)
between the Cold RA and Heat RA patient groups. 34 patients
received western medication such as methotrexate, sulfasalazine.
other DMARD’s and NSAID’s. 36 patients received Chinese
herbal medicine.
Clinical and Symptom Differences between RA Subtypes
After merging scoring categories containing less than 7
observations, 15 variables were left with only a single category.
There is no variation between the objects for these variables which
were therefore removed from the analysis: ‘Sudden shortness of
breath’, ‘Amount of phlegm’, ‘Sticky phlegm’, ‘Colored phlegm’,
‘Tender lower abdomen’, ‘Aggravated with pressure’, ‘Smelly
diarrhea’, ‘Chills S’, ‘Chills F’, ‘Fever with Chills’, ‘Pain aggravates
at night’, ‘Stabbing pain’, ‘Sharp pain’, ‘Deep pain’, ‘Heavy pain’.
After recoding, the data set used for further analysis contained 42
variables.
In the forced classification model the use of a 2nd degree
(quadratic) nonmonotonic spline (nominal analysis level) with 2
interior knots for the clinical measurements shows substantially
larger variance accounted for (11.8%) than a monotonic spline
(ordinal analysis level) (8.2%), indicating a nonmonotonic
relationship between the measurements. Also, a two interior knot
spline shows a larger variance (11.8%) than a one interior knot
spline (9.8%) (more knots allow for more freedom in the
transformation). Therefore a 2nd degree spline nominal analysis
level with two interior knots was chosen for the clinical chemistry
variables. A new model was then built using this analysis level and
used to select variables with a proportion of VAF .0.20. A model
was subsequently built including the 18 selected variables. The
model using splines with 2 interior knots for the clinical chemistry
variables was then compared once more with a model using one
interior knot. The results showed that the increase in total VAF in
the model with 2 interior knots was mostly due to the variable
MCHC. Therefore the final analysis level of the clinical variables
was adjusted to a 2nd degree spline with 1 interior knot, except for
MCHC which was set to 2 interior knots. The final model had a
total VAF of approximately 21% (see Table 2 for the loadings of
the 18 variables). The transformation plots of the clinical
chemistry variables of this model are included as supplementary
information (Figure S1). Leave two out cross validation resulted in
a classification error of 15%, which is substantially lower than the
expected error rate based on random classification (which is 50%).
RA patients that are classified as Heat by the Chinese medicine
expert are characterized with higher optimal quantifications on
average on the symptoms ‘red joints’, ‘swollen joints’, ‘warm
feeling’, ‘warm joints’, ‘dull pain’ and ‘pain that worsens with
Table 1. Patient characteristics.
Cold (n =20) Heat (n =19) p
Age (years) 51613 (24–74) 54611 (34–77) 0.44
Disease duration (months) 90690 (4–240) 1006100 (24–348) 0.44
Height (cm) 15964 (150–167) 16064 (155–170) 0.50
Weight (kg) 58618 (40–120) 5869 (37–75) 0.97
*Range is given in parenthesis.
doi:10.1371/journal.pone.0044331.t001
Table 2. Discriminating symptoms and clinical
measurements.
Variable name Loading
b17 MCHC 0.580
v40 Red joints 0.544
v39 Swollen joints 0.540
b37 IGG 0.504
v25 Warm feeling 0.495
b8 LY# 0.490
v41 Warm joints 0.490
v56 Dull pain 0.438
v50 Pain worsens by warmth and movement 0.399
b27 CHOL 0.370
b38 IGM 0.359
b19 PLT 0.285
b25 BUN 20.374
b32 ALT 20.419
v19 Cold feeling 20.457
v29 Aversion to cold 20.472
b18 RDW 20.475
b44 CCP 20.495
doi:10.1371/journal.pone.0044331.t002
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warmth and movement’, and with higher levels of the optimally
scaled clinical parameters mean corpuscular hemoglobin concen-
tration (MCHC), IgG, lymphocyte number (LY#), IgM, platelet
count (PLT) and cholesterol. Cold RA patients are best
characterized with higher optimal quantifications on average on
the symptoms ‘cold feeling’ and ‘aversion to cold’, and higher
levels of the optimally scaled clinical variables blood urea nitrogen
(BUN), alanine aminotransferase (ALT), red blood cell distribution
width (RDW) and anti-cyclic citrullinated protein antibodies
(CCP).
Both groups of patients have a similar average score on the
symptoms ‘pain’ and ‘stiff joints’ as well as on the clinical
parameters rheumatoid factor and c-reactive protein.
Urine and Plasma Metabolite Differences between RA
Subtypes
Urine samples of 14 of the 19 Heat RA and 14 of the 20 Cold
RA patients included in the analysis described above were
collected successfully for the LC-MS analysis. In total 11 urine
samples were either not collected at the hospital or the samples
were not send to the laboratory for metabolomics analysis. PLS-
DA analysis resulted in a final model containing 793 features. A
classification error of 14% was obtained by a double cross-
validation procedure. Permutation testing indicated that the error
rate of this model is significantly (p,0.05) different from the
distribution of models based on permuted classifications.
The tentative identification of the top 50 most discriminating
metabolites resulted in three metabolites that were verified by
comparing authentic standards with the samples: acetylcarnitine,
riboflavin and pantothenic acid. Thirteen of the top features
measured in positive ion mode as well as the acetylcarnitine
standard showed the same neutral loss of mass 59.0747 by
fragmentation, which is highly indicative of acylcarnitine com-
pounds [35,36]. The retention times of the features showing this
loss was increasing with the mass, indicating higher mass features
were less polar. This agrees with the fact that larger mass
acylcarnitines have longer fatty acid chains and are therefore less
polar. Furthermore, several glucuronides and soy isoflavones are
suspected, but the identity was not further determined (Table 3).
An LC-MS analysis of the plasma samples of 11 Cold RA and
14 Heat RA patients from the same set of patients that are used in
the urine metabolomics and questionnaire analysis was performed.
Three plasma samples were not available for analysis. Positive ion
mode features were not included in the multivariate analysis
because the QC samples were not stable. The PLS-DA analysis
resulted in a model containing 214 features (classification error of
28%). Permutation testing indicated that the error rate of this
model is significantly (p,0.05) different from the distribution of
models based on permuted classifications. Some of the top 50
features resulting from the PLS-DA model could be identified with
authentic standards (Table 4).
Discussion
The subtypes of RA patients are characterized by four sets of
features: clinical symptoms (questionnaire items), clinical chemistry
measurements in blood, metabolite measurements in urine and in
plasma. One hypothesis is that the Cold RA and Heat RA groups
have a different inflammatory status. Of the most discriminating
symptoms in the analysis, ‘warm joints’, ‘swollen joints’ and ‘red
joints’ indicate a difference in inflammatory status. However, c-
reactive protein (CRP), an important inflammation marker, was
not retained in the final model because of a low proportion of total
variance accounted for, based on the two groups. Rheumafactor
(RF), an important marker for RA disease activity [37], was not
retained in the model either. On the other hand, the lymphocyte
numbers are higher in Heat RA patients, although this level is not
considered elevated and indicative of inflammation in standard
evaluation [38]. A comparable average disease duration of 90 and
100 months for the two groups suggests that not one of the groups
can be considered an early arthritis or early aggressive arthritis
group. These observations indicate that the severity of inflamma-
tion might be different between the groups when the joint
symptoms are considered despite similar levels of rheumatoid
factor and c-reactive protein.
Swollen joint counts are routinely used to establish disease
activity in rheumatoid arthritis [39]. In Table 5 the percentages of
Cold and Heat patients with a positive score on zero to three of the
symptoms ‘warm joints’, ‘swollen joints’ or ‘red joints’ are given.
Even though high scores on the three symptoms are indicative for
the Heat group of RA patients, 40% of the Cold patients also have
a positive score on at least one of the three symptoms (frequencies
of the scored categories per class are included as supplementary
information Figure S2 and the raw symptom score data for
‘swollen joints’, ‘warm joints’ and ‘red joints’ is included as
supplementary Table S1). The data indicate that the same number
of patients in both groups are in pain and score a similar severity of
pain (data not shown). These symptom observations indicate that
the Heat RA group has much more joint problems than the Cold
RA group. It would be interesting to further study the role these
joint symptoms could play in sub-typing RA.
Our study shows that the important symptoms for the sub-
typing are ‘warm feeling’, ‘pain worsens by warmth and
movement’, ‘cold feeling’ and ‘aversion to cold’. This is in
agreement with a previous study in which a systems diagnosis of 49
patients with rheumatic diseases revealed ‘aversion to cold’,
‘aversion to heat’ and ‘cold feeling’ as highly relevant for the Cold
and Heat ranking of the subjects [23]. The symptom ‘aversion to
cold’ and coldness in general was found by others as well [12,40].
Our study and other studies of the biology of Cold and Heat types
Table 3. Top discriminating urine metabolites.
Importance Compound
2Log Cold/
Heatc
1 C8:1 acylcarnitineb 20.73
3 C10:3 acylcarnitineb 20.70
11 C8+OH acylcarnitineb 20.89
13 acetylcarnitinea 20.75
15 riboflavina 22.40
16 C11:1 acylcarnitineb 20.98
21 pantothenic acida 20.92
27 C6:DC acylcarnitineb 20.55
31 C5 acylcarnitineb 21.21
32 C10:2 acylcarnitineb 20.53
38 C8:2 acylcarnitineb 21.19
41 C10:1 acylcarnitineb 20.23
45 C9:3 acylcarnitineb 22.26
49 C10:3 acylcarnitine isotopeb 20.66
50 C6:2:DC acylcarnitineb 0.42
averified with authentic standard.
bverified with characteristic 59 neutral loss, retention time order, accurate mass.
cCalculated 2Log of the ratio between average levels in Cold and Heat patients.
doi:10.1371/journal.pone.0044331.t003
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of RA patients lead to the hypothesis that the currently unclear
effectiveness of cold and heat therapy might be improved by
targeting it to the right sub-type [41–43].
Anti-citrullinated protein antibody (CCP) is extensively studied
as a predictor of disease progression in RA [44]. In our
multivariate model, CCP levels were higher in RA Heat patients
suggesting that there might be a difference in disease progression
between the two subtypes. The clinical parameters with the
highest positive loadings were MCHC and IgG, while RDW
showed the highest negative loading next to CCP. Some
relationships between the Cold and Heat subtype and clinical
measurements are nonlinear (see supplementary Figure S1 for the
transformations of the variables). High as well as low serum levels
off MCHC result in a positively transformed value, which is
related to the Heat class. The highest levels of IgG are related to
the Cold RA type, while lower levels are not so clearly Cold or
Heat related. Blood urea nitrogen (BUN) levels increase in plasma
with serious kidney damage [45]. Higher or lower levels of BUN
are related to the Heat RA group, average levels are related to the
Cold RA group. Alanine aminotranferase (ALT) is an important
parameter to distinguish Cold and Heat patients, which has been
found to be related to insuline resistance and atherosclerosis risk in
RA patients [46].
The metabolomics analysis in this study revealed higher urine
levels of 11 acylcarnitines in the Heat group of RA patients. The
enzyme carnitine palmitoyltransferase I (CTP I), located in the
outer mitochondrial membrane, transfers acyl groups from
coenzyme A to carnitines allowing the transport of fatty acids
into the mitochondria for b-oxidation. Plasma carnitine levels are
maintained by a combination of dietary intake, endogenous
synthesis by the liver and kidneys and active renal reabsorption.
Acylcarnitines can leave the mitochondria, enter the blood stream
and can be excreted in urine [47].
Significantly lower total carnitine and acylcarnitine excretion in
urine of RA patients compared to healthy controls has been
reported, while free carnitine levels in urine and plasma are equal
in both groups [48,49]. Because dietary intake of carnitines was
equal in both groups, an impaired carnitine synthesis was
suggested which is controlled by skeletal muscle breakdown.
Decreased muscle mass and increased muscle turnover are
observed in RA patients, which might be explained by a reduced
CTP I activity. This was confirmed by a decreased creatinine and
3-methylhistidine excretion [49]. In this study we find that the
levels of a range of acylcarnitines are lower in the Cold RA group
than in the Heat RA group. These findings suggest that Cold RA
patients have less muscle mass and/or a more pronounced muscle
breakdown than RA Heat patients. A limitation of this study is that
the plasma acylcarnitine levels are not known. Further studies
should therefore be performed to validate the hypothesis that Cold
and Heat subtypes of RA patients are related to muscle mass or
muscle breakdown.
Decreased urine pantothenic acid and acylcarnitine levels have
been shown to indicate an increase in beta-oxidation in patients
using PPARa agonist drugs [50]. Peroxisome proliferator-activat-
ed receptors (PPAR) activate fatty acid and cholesterol catabolism
in the liver, activate gluconeogenesis and regulate amino acid
metabolism. In addition, PPAR activates CTP I and CTP II
activity. We report lower levels of pantothenic acid and
acylcarnitine levels in Cold RA patients which might therefore
indicate a difference in the activation of PPAR between the
groups.
Interestingly, CTP I activity is inhibited by omega-6 fatty acids
while an increased ratio of omega-3 versus omega-6 fatty acids
consumption stimulates fatty acid oxidation regulated by CTP I
activity [51]. A decrease in CTP I activity also seems to play a role
in Chronic Fatigue Syndrome patients. In these patients supple-
mentation with carnitine and acylcarnitine was found to decrease
fatigue symptoms [52]. These findings suggest that fatigue in
rheumatoid arthritis might be related to a decreased CTP I activity
and a changed carnitine homeostasis. Fatigue is one of the most
important factors in the disease experience of RA patients [53].
Our findings indicate that urine acylcarnitine levels are an
important discriminator between two subtypes of RA patients,
which might explain differences in the experience of fatigue. These
findings also suggest that carnitine and acylcarnitine supplemen-
tation might be beneficial for Cold RA patients and less so for
Heat RA patients. Further confirmatory studies should be
Table 4. Top discriminating plasma metabolites.
Importance Compounda 2Log Cold/Heatb
2 Dehydroepiandrosterone sulfate (DHEA sulfate) 20.96
4 4-Methyl-2-oxovaleric acid 20.25
6 Indoxyl sulfate 20.44
10 Uric acid 20.25
11 Cholesterol sulfate 20.65
13 3-Methyl-2-oxovaleric acid 20.26
47 Tryptophan 20.23
50 Alpha-ketoisovaleric acid 20.13
aall compounds are verified with an authentic standard.
bCalculated Log of the ratio between average levels in Cold and Heat patients.
doi:10.1371/journal.pone.0044331.t004
Table 5. Warm, swollen & red joint scores.
# Symptoms Cold* Heat*
0 60 26
$1 40 74
$2 10 74
3 5 63
*Percentages of subjects showing a positive score on a minimum of 0, 1, 2 or 3
of the symptoms.
doi:10.1371/journal.pone.0044331.t005
Sub-Typing Rheumatoid Arthritis
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e44331
conducted to prove this hypothesis and develop this targeted
treatment option.
Significantly lower DHEAS levels have been reported in
premenopausal RA patients and are correlated to low morning
cortisol levels and high IL-6 levels indicating a suppression of
HPA-axis function [54]. Decreased HPA-axis function is associ-
ated with a decreased stress response which results in an
inadequate response to stress factors. It is hypothesized that this
inadequate response can lead to autoimmune and inflammatory
disorders [54]. This study shows a higher DHEAS levels in Heat
RA patients compared to Cold RA patients suggesting that the
Cold RA group has a more suppressed HPA-axis function. A text
mining study [55] has shown that diseases related to Cold
according to Chinese medicine theory are more related to
hormone function disturbances and Heat related diseases to
immune function disturbances, which is in agreement with our
findings.
This study provides metabolite, symptom and clinical chemistry
profiles for two subtypes of rheumatoid arthritis. The profiles
indicate a number of biological processes that seem to be regulated
differently in the two groups. RA therapy could be optimized for
the two groups in various ways. This study suggests differences in
the effects of carnitine and acylcarnitine supplementation for the
two groups as well as differences in the effects of hormone
treatments such as prednison. We think that the better character-
ization and biological understanding of Cold and Heat RA offered
in this study can be used to tailor therapy to each subgroup.
Additionally, this study offers a new subtype to include in studies
aiming for an improvement of response to treatment. Finally, the
mechanism and effect of specific Cold RA and Heat RA treatment
options used in Chinese medicine should be studied and might be
integrated in standard disease management strategies by using a
standardized Cold RA and Heat RA diagnostic profile.
Supporting Information
Figure S1 Transformation plots of the clinical chemis-
try variables. On the x-axis the categories of the original
discretized variables are represented while on the y-axis the
optimally scaled quantifications are shown. A negative quantifica-
tion corresponds to the Cold classification and a positive
quantification to the Heat classification.
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Figure S2 Frequencies of scored categories per class.
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Table S1 Raw data of ‘swollen joints’, ‘warm joints’ and
‘red joints’ scores acquired by the symptom question-
naire. Patients were asked to give a score between 1 and 7. For
the construction of Table 5 the positive scores, scores higher than
1, were counted for the Cold RA and Heat RA group. In Table S1
mean ranks for the Cold RA and Heat RA groups are given for
each symptom and the differences between the groups are
evaluated with the Mann-Whitney U test. The scoring of the
three symptoms is significantly different between the Cold RA and
Heat RA group.
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Text S1 Symptoms questionnaire.
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